Continuous Renal Replacement Therapy Market by Product (Hemofilter, Bloodline, Machines, Dialysates), Modality (SCUF, CVVH, CVVHD, CVVHDF), Age (Adult, Pediatric), Enduser (Hospitals, Ambulatory), and Region - Global Forecast to 2028
The global Continuous renal replacement therapy therapy market size is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 8.1% during the forecast period.
Various factors such as increasing incidences of Acute kidney injyury (AKI) and rising prominence on effective renal replacement therapy among patients in ICU and critically ill patients are majorly attributing to the rise in the demand for CRRT system and disposables. Moreover, the technologically advanced CRRT system in the market and rising prevalence of hypertension and rising cases of Acute kidney injury, are some of the factors which are anticipated to drive the demand for Continuous renal replacement therapy therapy during the forecast period.
“The dialysate and replacement fluid segment to capture the largest share in Continuous renal replacement therapy therapy market, by product, during the forecast period.”
The dialysate and replacement fluid segment is expected to witness the high growth rate during the forecast period. The high growth owes to the significant increase in the demand for CRRT in the treatment for the patients who are unstablehemodynamically , the increase in the number of manufacturers who are offering dialysate and replacement fluids for renal replacement therapy, and also the strong presence of players in the market.
“The continuous venovenous hemodiafiltration segment to witness highest growth rate in Continuous renal replacement therapy therapy market, by modality in 2022.”
The continuous venovenous hemodiafiltration modality segment is expected to witness the highest growth rate in the CRRT market during the forecast period. The rising preference of continuous venovenous hemodiafiltrationmodality among nephrologists and critical care physicians, and also the advantages which includes better clearance of medium-sized solutes in comparison to hemodialysis (accurate acid-base balance without intervention, and a significant reduction in CRRT-related phosphate depletion area are some of the factors which supports the growth of the segment in the coming years.
“The Hospital segment accounted for the largest share of the Continuous renal replacement therapy therapy, by age group, in 2022”
The CRRT process mainly adopted in hospitals due to its technological advancements and cost of investment. The economical stability of hospitals among other end users has led to its larger market share. The continuous renal replacement therapy (CRRT) is mostly used treatment in hospitals, especially in the intensive care unit (ICU) or the patients who are critically ill. It can help to stabilize hemodynamic parameters and improve clinical symptoms and organ function in patients, which can help to reduce complications
“The Asia Pacific market to grow at the highest CAGR during the forecast period.”
The Continuous renal replacementtherapy market is segmented into five major regions, , North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The increase in the awareness of Continuous renal replacement therapy therapy, increasing healthcare expenditures, rising of the disposable incomes , rising incidences of sepsis, increasing prevalence of hypertension & diabetes (major causes of AKI), the high use of CRRT in Australia and Japan, , and increasing accessibility to CRRT for AKI treatment are some of the key factors that are playing major role in increase of adoption of the CRRT systems in Asia Pacific region
Breakdown of supply-side primary interviews:
Research Coverage
This report studies the Continuous renal replacement therapy therapy market based on the product, modality, age group, end users and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Key Benefits of Buying the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below-mentioned five strategies.
This report provides insights into the following pointers:
Various factors such as increasing incidences of Acute kidney injyury (AKI) and rising prominence on effective renal replacement therapy among patients in ICU and critically ill patients are majorly attributing to the rise in the demand for CRRT system and disposables. Moreover, the technologically advanced CRRT system in the market and rising prevalence of hypertension and rising cases of Acute kidney injury, are some of the factors which are anticipated to drive the demand for Continuous renal replacement therapy therapy during the forecast period.
“The dialysate and replacement fluid segment to capture the largest share in Continuous renal replacement therapy therapy market, by product, during the forecast period.”
The dialysate and replacement fluid segment is expected to witness the high growth rate during the forecast period. The high growth owes to the significant increase in the demand for CRRT in the treatment for the patients who are unstablehemodynamically , the increase in the number of manufacturers who are offering dialysate and replacement fluids for renal replacement therapy, and also the strong presence of players in the market.
“The continuous venovenous hemodiafiltration segment to witness highest growth rate in Continuous renal replacement therapy therapy market, by modality in 2022.”
The continuous venovenous hemodiafiltration modality segment is expected to witness the highest growth rate in the CRRT market during the forecast period. The rising preference of continuous venovenous hemodiafiltrationmodality among nephrologists and critical care physicians, and also the advantages which includes better clearance of medium-sized solutes in comparison to hemodialysis (accurate acid-base balance without intervention, and a significant reduction in CRRT-related phosphate depletion area are some of the factors which supports the growth of the segment in the coming years.
“The Hospital segment accounted for the largest share of the Continuous renal replacement therapy therapy, by age group, in 2022”
The CRRT process mainly adopted in hospitals due to its technological advancements and cost of investment. The economical stability of hospitals among other end users has led to its larger market share. The continuous renal replacement therapy (CRRT) is mostly used treatment in hospitals, especially in the intensive care unit (ICU) or the patients who are critically ill. It can help to stabilize hemodynamic parameters and improve clinical symptoms and organ function in patients, which can help to reduce complications
“The Asia Pacific market to grow at the highest CAGR during the forecast period.”
The Continuous renal replacementtherapy market is segmented into five major regions, , North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The increase in the awareness of Continuous renal replacement therapy therapy, increasing healthcare expenditures, rising of the disposable incomes , rising incidences of sepsis, increasing prevalence of hypertension & diabetes (major causes of AKI), the high use of CRRT in Australia and Japan, , and increasing accessibility to CRRT for AKI treatment are some of the key factors that are playing major role in increase of adoption of the CRRT systems in Asia Pacific region
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1: 25%, Tier 2: 30%, and Tier 3: 45%
- By Designation: C-level: 26%, D-level: 30%, and Others: 44%
- By Region: North America: 40%, Europe: 31%, APAC: 20%, Latin America: 6%, and the Middle East & Africa: 3%
Research Coverage
This report studies the Continuous renal replacement therapy therapy market based on the product, modality, age group, end users and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Key Benefits of Buying the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below-mentioned five strategies.
This report provides insights into the following pointers:
- Market Driver: The growth of the market attributes to increase of advanced technology and benefits of using CRRT systems.
- Market Penetration: Comprehensive information on the product portfolios of the top players in the Continuous renal replacement therapy market. The report analyzes the market based on the product, modality, age group, end users and region.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the Continuous renal replacement therapy market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for Continuous renal replacement therapy across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the Continuous renal replacement therapy market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the Continuous renal replacement therapy market
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: REGIONAL SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 MAJOR MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from industry experts
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARIES: CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) MARKET
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 7 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: BAXTER INTERNATIONAL INC.
FIGURE 9 REVENUE SHARE ANALYSIS FOR TOP PLAYERS
FIGURE 10 DEMAND-SIDE MARKET ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
FIGURE 11 DEMAND-SIDE MARKET ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY CONSUMABLES
FIGURE 12 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET (2023–2028)
FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 14 TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
FIGURE 15 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
2.6 LIMITATIONS
2.7 METHODOLOGY-RELATED LIMITATIONS
2.8 RECESSION IMPACT
3 EXECUTIVE SUMMARY
FIGURE 16 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 17 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2023 VS. 2028 (USD MILLION)
FIGURE 18 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2023 VS. 2028 (USD MILLION)
FIGURE 19 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 20 GEOGRAPHICAL SNAPSHOT OF CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
4 PREMIUM INSIGHTS
4.1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET OVERVIEW
FIGURE 21 RISING PREVALENCE OF ACUTE KIDNEY INJURY AND GROWING AWARENESS OF CRRT TO DRIVE MARKET
4.2 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT AND COUNTRY (2022)
FIGURE 22 DIALYSATE & REPLACEMENT FLUIDS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
4.3 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 23 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
4.4 REGIONAL MIX: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET (2021–2028)
FIGURE 24 NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
4.5 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: EMERGING VS. DEVELOPED MARKETS
FIGURE 25 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 26 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of acute kidney injury (AKI)
FIGURE 27 GLOBAL INCIDENCE OF ACUTE KIDNEY INJURY, 2010 VS. 2015 VS. 2020
TABLE 2 NUMBER OF PEOPLE AGED 65 OR OVER, BY REGION, 2019 VS. 2050
5.2.1.2 Growing number of ICU patients with AKI and increasing incidence of sepsis
FIGURE 28 IMPACT OF ICU-ACQUIRED AKI IN US
5.2.1.3 Increasing clinical advantage of CRRT over intermittent blood purification
5.2.1.4 Technological advancements and new product launches
5.2.1.5 Growing prevalence of diabetes and hypertension
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulatory guidelines in North America
5.2.2.2 High procedural cost of CRRT
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets in Asia Pacific and RoW
5.2.3.2 Increasing applications of CRRT
5.2.3.2.1 Evolution of CRRT from simple renal replacement treatment to multi-organ support therapy
5.2.3.2.2 Progression of CRRT from adaptive renal devices to multipurpose treatment machines
5.2.3.3 Ongoing research to establish safety and efficacy profile of CRRT
5.2.3.4 Development of CRRT systems for pediatric patients
5.2.3.4.1 The CARPEDIEM Project
5.2.3.5 Untapped growth opportunities in North America
5.2.4 CHALLENGES
5.2.4.1 High complexity of CRRT
5.2.4.2 Lack of standard treatment guidelines in developing nations
5.2.4.3 Shortage of trained ICU professionals in developing nations
5.2.4.4 Poor reimbursement scenario in developing countries
5.2.4.5 Lack of awareness about benefits of CRRT
5.3 REGULATORY ANALYSIS
5.3.1 NORTH AMERICA
5.3.2 EUROPE
5.3.3 ASIA PACIFIC
5.3.3.1 India
5.3.3.2 China
5.3.3.3 Japan
5.3.3.4 South Korea
5.3.4 REST OF THE WORLD (ROW)
5.3.4.1 Brazil
5.3.4.2 Argentina
5.4 REIMBURSEMENT SCENARIO
5.4.1 NORTH AMERICA
5.4.2 EUROPE
5.4.3 ASIA PACIFIC
5.4.3.1 Japan
5.4.4 REST OF THE WORLD (ROW)
5.4.4.1 Brazil
5.4.4.2 Central America and the Caribbean
5.5 KEY CONFERENCES & EVENTS
TABLE 3 KEY CONFERENCES & EVENTS, 2023
5.6 PATENT ANALYSIS
5.6.1 PATENT PUBLICATION TRENDS FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
FIGURE 29 PATENT PUBLICATION TRENDS (JANUARY 2013–AUGUST 2023)
5.6.2 INSIGHTS ON JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR CONTINUOUS RENAL REPLACEMENT PATENTS, 2013–2023
FIGURE 31 TOP 10 APPLICANT COUNTRIES/REGIONS FOR CONTINUOUS RENAL REPLACEMENT PATENTS, 2013–2023
TABLE 4 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: LIST OF MAJOR PATENTS
5.7 TRADE ANALYSIS
5.8 TECHNOLOGY ANALYSIS
5.8.1 MINIMALLY INVASIVE CRRT
5.8.2 CRRT IN COMBINATION WITH OTHER THERAPIES
5.9 ECOSYSTEM ANALYSIS
5.10 VALUE CHAIN ANALYSIS
FIGURE 32 VALUE CHAIN OF CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
5.11 PRICING TREND ANALYSIS
TABLE 5 AVERAGE PRICE OF CRRT SYSTEMS AND CONSUMABLES, BY COUNTRY, 2020 (USD)
5.12 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
TABLE 7 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
5.13.2 BUYING CRITERIA
FIGURE 34 KEY BUYING CRITERIA FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
TABLE 8 KEY BUYING CRITERIA FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
5.14 ARTIFICIAL INTELLIGENCE INTEGRATION IN CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS
5.15 UNMET NEED & END-USER EXPECTATIONS WITH CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS
6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 9 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 DIALYSATE & REPLACEMENT FLUIDS
6.2.1 RISING DEMAND FOR DIALYSATE TO DRIVE MARKET
TABLE 10 DIALYSATE & REPLACEMENT FLUIDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 DISPOSABLES
TABLE 11 DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 12 DISPOSABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3.1 HEMOFILTERS
6.3.1.1 Widely adopted during CRRT procedures for treatment of AKI
TABLE 13 HEMOFILTERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3.2 BLOODLINE SETS & TUBES
6.3.2.1 Development of blood tubing with special coding to prevent clotting to offer growth opportunities
TABLE 14 BLOODLINE SETS & TUBES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3.3 OTHER DISPOSABLES
TABLE 15 OTHER DISPOSABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 CRRT SYSTEMS
6.4.1 AVAILABILITY OF TECHNOLOGICALLY ADVANCED, EASY-TO-USE SYSTEMS TO BOOST MARKET GROWTH
TABLE 16 CRRT SYSTEMS MARKET BY COUNTRY, 2021–2028 (USD MILLION)
7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY
7.1 INTRODUCTION
TABLE 17 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
7.2 CONTINUOUS VENOVENOUS HEMOFILTRATION
7.2.1 WIDESPREAD ADOPTION IN TREATMENT OF ACUTE KIDNEY INJURY TO DRIVE MARKET
TABLE 18 CONTINUOUS VENOVENOUS HEMOFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 CONTINUOUS VENOVENOUS HEMODIAFILTRATION
7.3.1 USED IN PATIENTS WITH CONGESTIVE HEART FAILURE
TABLE 19 CONTINUOUS VENOVENOUS HEMODIAFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 CONTINUOUS VENOVENOUS HEMODIALYSIS
7.4.1 MORE EFFECTIVE IN REMOVING SMALL TO MEDIUM-SIZED MOLECULES COMPARED TO OTHER CRRT MODALITIES
TABLE 20 CONTINUOUS VENOVENOUS HEMODIALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 SLOW CONTINUOUS ULTRAFILTRATION
7.5.1 DOES NOT USE DIALYSATE OR REPLACEMENT FLUIDS FOR REMOVAL OF EXCESS FLUID FROM BLOODSTREAM
TABLE 21 SLOW CONTINUOUS ULTRAFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP
8.1 INTRODUCTION
TABLE 22 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
8.2 ADULTS
8.2.1 LARGEST AND FASTEST-GROWING SEGMENT OF MARKET
TABLE 23 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR ADULTS, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 PEDIATRICS & NEONATES
8.3.1 HIGH PREVALENCE OF AKI IN NEONATES TO SUPPORT MARKET GROWTH
TABLE 24 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR PEDIATRICS & NEONATES, BY COUNTRY, 2021–2028 (USD MILLION)
9 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER
9.1 INTRODUCTION
TABLE 25 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 HOSPITALS
9.2.1 FASTEST-GROWING END-USER SEGMENT
TABLE 26 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 AMBULATORY CARE
9.3.1 REDUCED INPATIENT STAY TO SUPPORT MARKET GROWTH
TABLE 27 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR AMBULATORY CARE, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 HOME CARE
9.4.1 RISING ADOPTION OF PORTABLE AND HOME-BASED DEVICES TO AID MARKET GROWTH
TABLE 28 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR HOME CARE, BY COUNTRY, 2021–2028 (USD MILLION)
9.5 OTHER END USERS
TABLE 29 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
10 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION
10.1 INTRODUCTION
TABLE 30 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
10.2.1 NORTH AMERICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
FIGURE 35 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT
TABLE 31 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 32 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 33 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 34 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 35 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 36 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.2 US
10.2.2.1 Large number of AKI patients to drive market
TABLE 37 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 38 US: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 39 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 40 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 41 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 High cost of CRRT to negatively impact market growth
TABLE 42 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 43 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 44 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 45 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 46 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
10.3.1 EUROPEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
TABLE 47 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 49 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 50 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 51 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Largest market for continuous renal replacement therapy in Europe
TABLE 53 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 54 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 55 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 56 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 57 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Rising number of sepsis cases to support market growth
TABLE 58 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 59 UK: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 60 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 61 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 62 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Growing AKI patient population to propel market growth
TABLE 63 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 64 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 65 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 66 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 67 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Government initiatives to promote awareness of renal care to drive market
TABLE 68 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 69 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 70 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 71 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 72 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Favorable reimbursement scenario to favor market growth
TABLE 73 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 74 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 75 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 76 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 77 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 78 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 79 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 80 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 81 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 82 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
FIGURE 36 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT
TABLE 83 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 86 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 87 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 88 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Well-established medical infrastructure to support market growth
TABLE 89 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 90 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 91 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 92 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 93 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Increasing prevalence of ESRD and AKI to boost demand for CRRT
TABLE 94 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 95 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 96 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 97 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 98 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Large patient population to support market growth
TABLE 99 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 100 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 101 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 102 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 103 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 AUSTRALIA
10.4.5.1 Government initiatives to increase adoption of CRRT
TABLE 104 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 105 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 106 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 107 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 108 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.6 SOUTH KOREA
10.4.6.1 Increasing awareness through online education programs and events to aid market growth
TABLE 109 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 110 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 111 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 112 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 113 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.7 REST OF ASIA PACIFIC
TABLE 114 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 115 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 116 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 117 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 118 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 LATIN AMERICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
TABLE 119 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 120 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 121 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 122 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 123 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 124 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.2 BRAZIL
10.5.2.1 Rising incidence of AKI to drive market
TABLE 125 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 126 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 127 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 128 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 129 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.3 MEXICO
10.5.3.1 Large patient population to drive market
TABLE 130 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 131 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 132 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 133 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 134 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.4 REST OF LATIN AMERICA
TABLE 135 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 136 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 138 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 139 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 LACK OF AWARENESS REGARDING CRRT TO RESTRAIN MARKET GROWTH
10.6.2 MIDDLE EAST AND AFRICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
TABLE 140 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 141 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 142 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 143 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 144 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
FIGURE 37 GROWTH STRATEGIES ADOPTED BY KEY PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
11.2 REVENUE SHARE ANALYSIS OF MARKET PLAYERS, 2018–2022 (USD MILLION)
FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
FIGURE 39 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
TABLE 145 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DEGREE OF COMPETITION
11.3 COMPANY EVALUATION MATRIX
11.3.1 STARS
11.3.2 EMERGING LEADERS
11.3.3 PERVASIVE PLAYERS
11.3.4 PARTICIPANTS
FIGURE 40 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPANY EVALUATION MATRIX, 2022
11.4 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
11.4.1 PROGRESSIVE COMPANIES
11.4.2 STARTING BLOCKS
11.4.3 RESPONSIVE COMPANIES
11.4.4 DYNAMIC COMPANIES
FIGURE 41 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
11.5 FOOTPRINT ANALYSIS OF PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
TABLE 146 PRODUCT, REGIONAL, AND END-USER FOOTPRINT ANALYSIS OF PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
TABLE 147 PRODUCT FOOTPRINT OF COMPANIES
TABLE 148 END-USER FOOTPRINT OF COMPANIES
TABLE 149 REGIONAL FOOTPRINT OF COMPANIES
11.6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: PRODUCT LAUNCHES AND REGULATORY APPROVALS (JANUARY 2019 TO AUGUST 2023)
TABLE 150 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
11.7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DEALS (JANUARY 2019 TO AUGUST 2023)
TABLE 151 KEY DEALS
11.8 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: OTHER DEVELOPMENTS (JANUARY 2019 TO AUGUST 2023)
TABLE 152 OTHER KEY DEVELOPMENTS
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1 MAJOR PLAYERS
12.1.1 BAXTER INTERNATIONAL, INC.
TABLE 153 BAXTER INTERNATIONAL, INC.: BUSINESS OVERVIEW
FIGURE 42 BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022)
TABLE 154 BAXTER INTERNATIONAL, INC.: PRODUCT OFFERINGS
12.1.2 FRESENIUS MEDICAL CARE AG & CO. KGAA
TABLE 155 FRESENIUS MEDICAL CARE AG & CO. KGAA: BUSINESS OVERVIEW
FIGURE 43 FRESENIUS MEDICAL CARE AG & CO. KGAA: COMPANY SNAPSHOT (2022)
TABLE 156 FRESENIUS MEDICAL CARE AG & CO. KGAA: PRODUCT OFFERINGS
12.1.3 NIKKISO CO., LTD.
TABLE 157 NIKKISO CO., LTD.: BUSINESS OVERVIEW
FIGURE 44 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022)
TABLE 158 NIKKISO CO., LTD.: PRODUCT OFFERINGS
12.1.4 B. BRAUN MELSUNGEN AG
TABLE 159 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
FIGURE 45 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2022)
TABLE 160 B. BRAUN MELSUNGEN AG: PRODUCT OFFERINGS
12.1.5 MEDTRONIC PLC
TABLE 161 MEDTRONIC PLC: BUSINESS OVERVIEW
FIGURE 46 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)
TABLE 162 MEDTRONIC PLC: PRODUCT OFFERINGS
12.1.6 ASAHI KASEI CORPORATION
TABLE 163 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
FIGURE 47 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 164 ASAHI KASEI CORPORATION: PRODUCT OFFERINGS
12.1.7 TORAY MEDICAL CO., LTD.
TABLE 165 TORAY MEDICAL CO., LTD.: BUSINESS OVERVIEW
FIGURE 48 TORAY MEDICAL CO., LTD.: COMPANY SNAPSHOT (2022)
TABLE 166 TORAY MEDICAL CO., LTD.: PRODUCT OFFERINGS
12.1.8 NIPRO CORPORATION
TABLE 167 NIPRO CORPORATION: BUSINESS OVERVIEW
FIGURE 49 NIPRO CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 168 NIPRO CORPORATION: PRODUCT OFFERINGS
12.1.9 INFOMED SA
TABLE 169 INFOMED SA: BUSINESS OVERVIEW
TABLE 170 INFOMED SA: PRODUCT OFFERINGS
12.1.10 MEDICA SPA
TABLE 171 MEDICA SPA: BUSINESS OVERVIEW
TABLE 172 MEDICA SPA: PRODUCT OFFERINGS
12.1.11 MEDITES PHARMA SPOL. S.R.O.
TABLE 173 MEDITES PHARMA SPOL. S.R.O.: BUSINESS OVERVIEW
TABLE 174 MEDITES PHARMA SPOL. S.R.O.: PRODUCT OFFERINGS
12.1.12 MEDICAL COMPONENTS, INC.
TABLE 175 MEDICAL COMPONENTS, INC.: BUSINESS OVERVIEW
TABLE 176 MEDICAL COMPONENTS, INC.: PRODUCT OFFERINGS
12.1.13 SWS HEMODIALYSIS CARE CO., LTD.
TABLE 177 SWS HEMODIALYSIS CARE CO., LTD.: BUSINESS OVERVIEW
TABLE 178 SWS HEMODIALYSIS CARE CO., LTD.: PRODUCT OFFERINGS
12.1.14 NINGBO TIANYI MEDICAL DEVICES CO., LTD.
TABLE 179 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: BUSINESS OVERVIEW
TABLE 180 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: PRODUCT OFFERINGS
12.1.15 ANJUE MEDICAL EQUIPMENT CO., LTD.
TABLE 181 ANJUE MEDICAL EQUIPMENT CO., LTD.: BUSINESS OVERVIEW
TABLE 182 ANJUE MEDICAL EQUIPMENT CO., LTD.: PRODUCT OFFERINGS
12.1.16 KIMAL
TABLE 183 KIMAL: BUSINESS OVERVIEW
TABLE 184 KIMAL.: PRODUCT OFFERINGS
12.1.17 JIANGXI SANXIN MEDTEC CO., LTD.
TABLE 185 JIANGXI SANXIAN MEDTECH CO., LTD.: BUSINESS OVERVIEW
TABLE 186 JIANGXI SANXIAN MEDTECH CO., LTD.: PRODUCT OFFERINGS
12.2 OTHER PLAYERS
12.2.1 ALLMED MEDICAL PRODUCTS CO., LTD.
12.2.2 DIALCO MEDICAL INC.
12.2.3 BROWNDOVE HEALTHCARE PVT. LTD.
12.2.4 STERIS PLC
12.2.5 KURARAY MEDICAL PLC
12.2.6 LIVANOVA PLC
12.2.7 DIAVERUM DEUTSCHLAND GMBH
12.2.8 SEMBCORP INDUSTRIES
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: REGIONAL SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 MAJOR MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from industry experts
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARIES: CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) MARKET
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 7 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: BAXTER INTERNATIONAL INC.
FIGURE 9 REVENUE SHARE ANALYSIS FOR TOP PLAYERS
FIGURE 10 DEMAND-SIDE MARKET ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
FIGURE 11 DEMAND-SIDE MARKET ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY CONSUMABLES
FIGURE 12 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET (2023–2028)
FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 14 TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
FIGURE 15 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
2.6 LIMITATIONS
2.7 METHODOLOGY-RELATED LIMITATIONS
2.8 RECESSION IMPACT
3 EXECUTIVE SUMMARY
FIGURE 16 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 17 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2023 VS. 2028 (USD MILLION)
FIGURE 18 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2023 VS. 2028 (USD MILLION)
FIGURE 19 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 20 GEOGRAPHICAL SNAPSHOT OF CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
4 PREMIUM INSIGHTS
4.1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET OVERVIEW
FIGURE 21 RISING PREVALENCE OF ACUTE KIDNEY INJURY AND GROWING AWARENESS OF CRRT TO DRIVE MARKET
4.2 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT AND COUNTRY (2022)
FIGURE 22 DIALYSATE & REPLACEMENT FLUIDS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
4.3 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 23 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
4.4 REGIONAL MIX: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET (2021–2028)
FIGURE 24 NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
4.5 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: EMERGING VS. DEVELOPED MARKETS
FIGURE 25 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 26 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of acute kidney injury (AKI)
FIGURE 27 GLOBAL INCIDENCE OF ACUTE KIDNEY INJURY, 2010 VS. 2015 VS. 2020
TABLE 2 NUMBER OF PEOPLE AGED 65 OR OVER, BY REGION, 2019 VS. 2050
5.2.1.2 Growing number of ICU patients with AKI and increasing incidence of sepsis
FIGURE 28 IMPACT OF ICU-ACQUIRED AKI IN US
5.2.1.3 Increasing clinical advantage of CRRT over intermittent blood purification
5.2.1.4 Technological advancements and new product launches
5.2.1.5 Growing prevalence of diabetes and hypertension
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulatory guidelines in North America
5.2.2.2 High procedural cost of CRRT
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets in Asia Pacific and RoW
5.2.3.2 Increasing applications of CRRT
5.2.3.2.1 Evolution of CRRT from simple renal replacement treatment to multi-organ support therapy
5.2.3.2.2 Progression of CRRT from adaptive renal devices to multipurpose treatment machines
5.2.3.3 Ongoing research to establish safety and efficacy profile of CRRT
5.2.3.4 Development of CRRT systems for pediatric patients
5.2.3.4.1 The CARPEDIEM Project
5.2.3.5 Untapped growth opportunities in North America
5.2.4 CHALLENGES
5.2.4.1 High complexity of CRRT
5.2.4.2 Lack of standard treatment guidelines in developing nations
5.2.4.3 Shortage of trained ICU professionals in developing nations
5.2.4.4 Poor reimbursement scenario in developing countries
5.2.4.5 Lack of awareness about benefits of CRRT
5.3 REGULATORY ANALYSIS
5.3.1 NORTH AMERICA
5.3.2 EUROPE
5.3.3 ASIA PACIFIC
5.3.3.1 India
5.3.3.2 China
5.3.3.3 Japan
5.3.3.4 South Korea
5.3.4 REST OF THE WORLD (ROW)
5.3.4.1 Brazil
5.3.4.2 Argentina
5.4 REIMBURSEMENT SCENARIO
5.4.1 NORTH AMERICA
5.4.2 EUROPE
5.4.3 ASIA PACIFIC
5.4.3.1 Japan
5.4.4 REST OF THE WORLD (ROW)
5.4.4.1 Brazil
5.4.4.2 Central America and the Caribbean
5.5 KEY CONFERENCES & EVENTS
TABLE 3 KEY CONFERENCES & EVENTS, 2023
5.6 PATENT ANALYSIS
5.6.1 PATENT PUBLICATION TRENDS FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
FIGURE 29 PATENT PUBLICATION TRENDS (JANUARY 2013–AUGUST 2023)
5.6.2 INSIGHTS ON JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR CONTINUOUS RENAL REPLACEMENT PATENTS, 2013–2023
FIGURE 31 TOP 10 APPLICANT COUNTRIES/REGIONS FOR CONTINUOUS RENAL REPLACEMENT PATENTS, 2013–2023
TABLE 4 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: LIST OF MAJOR PATENTS
5.7 TRADE ANALYSIS
5.8 TECHNOLOGY ANALYSIS
5.8.1 MINIMALLY INVASIVE CRRT
5.8.2 CRRT IN COMBINATION WITH OTHER THERAPIES
5.9 ECOSYSTEM ANALYSIS
5.10 VALUE CHAIN ANALYSIS
FIGURE 32 VALUE CHAIN OF CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
5.11 PRICING TREND ANALYSIS
TABLE 5 AVERAGE PRICE OF CRRT SYSTEMS AND CONSUMABLES, BY COUNTRY, 2020 (USD)
5.12 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
TABLE 7 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
5.13.2 BUYING CRITERIA
FIGURE 34 KEY BUYING CRITERIA FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
TABLE 8 KEY BUYING CRITERIA FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
5.14 ARTIFICIAL INTELLIGENCE INTEGRATION IN CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS
5.15 UNMET NEED & END-USER EXPECTATIONS WITH CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS
6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 9 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 DIALYSATE & REPLACEMENT FLUIDS
6.2.1 RISING DEMAND FOR DIALYSATE TO DRIVE MARKET
TABLE 10 DIALYSATE & REPLACEMENT FLUIDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 DISPOSABLES
TABLE 11 DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 12 DISPOSABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3.1 HEMOFILTERS
6.3.1.1 Widely adopted during CRRT procedures for treatment of AKI
TABLE 13 HEMOFILTERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3.2 BLOODLINE SETS & TUBES
6.3.2.1 Development of blood tubing with special coding to prevent clotting to offer growth opportunities
TABLE 14 BLOODLINE SETS & TUBES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3.3 OTHER DISPOSABLES
TABLE 15 OTHER DISPOSABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 CRRT SYSTEMS
6.4.1 AVAILABILITY OF TECHNOLOGICALLY ADVANCED, EASY-TO-USE SYSTEMS TO BOOST MARKET GROWTH
TABLE 16 CRRT SYSTEMS MARKET BY COUNTRY, 2021–2028 (USD MILLION)
7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY
7.1 INTRODUCTION
TABLE 17 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
7.2 CONTINUOUS VENOVENOUS HEMOFILTRATION
7.2.1 WIDESPREAD ADOPTION IN TREATMENT OF ACUTE KIDNEY INJURY TO DRIVE MARKET
TABLE 18 CONTINUOUS VENOVENOUS HEMOFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 CONTINUOUS VENOVENOUS HEMODIAFILTRATION
7.3.1 USED IN PATIENTS WITH CONGESTIVE HEART FAILURE
TABLE 19 CONTINUOUS VENOVENOUS HEMODIAFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 CONTINUOUS VENOVENOUS HEMODIALYSIS
7.4.1 MORE EFFECTIVE IN REMOVING SMALL TO MEDIUM-SIZED MOLECULES COMPARED TO OTHER CRRT MODALITIES
TABLE 20 CONTINUOUS VENOVENOUS HEMODIALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 SLOW CONTINUOUS ULTRAFILTRATION
7.5.1 DOES NOT USE DIALYSATE OR REPLACEMENT FLUIDS FOR REMOVAL OF EXCESS FLUID FROM BLOODSTREAM
TABLE 21 SLOW CONTINUOUS ULTRAFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP
8.1 INTRODUCTION
TABLE 22 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
8.2 ADULTS
8.2.1 LARGEST AND FASTEST-GROWING SEGMENT OF MARKET
TABLE 23 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR ADULTS, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 PEDIATRICS & NEONATES
8.3.1 HIGH PREVALENCE OF AKI IN NEONATES TO SUPPORT MARKET GROWTH
TABLE 24 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR PEDIATRICS & NEONATES, BY COUNTRY, 2021–2028 (USD MILLION)
9 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER
9.1 INTRODUCTION
TABLE 25 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 HOSPITALS
9.2.1 FASTEST-GROWING END-USER SEGMENT
TABLE 26 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 AMBULATORY CARE
9.3.1 REDUCED INPATIENT STAY TO SUPPORT MARKET GROWTH
TABLE 27 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR AMBULATORY CARE, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 HOME CARE
9.4.1 RISING ADOPTION OF PORTABLE AND HOME-BASED DEVICES TO AID MARKET GROWTH
TABLE 28 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR HOME CARE, BY COUNTRY, 2021–2028 (USD MILLION)
9.5 OTHER END USERS
TABLE 29 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
10 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION
10.1 INTRODUCTION
TABLE 30 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
10.2.1 NORTH AMERICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
FIGURE 35 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT
TABLE 31 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 32 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 33 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 34 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 35 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 36 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.2 US
10.2.2.1 Large number of AKI patients to drive market
TABLE 37 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 38 US: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 39 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 40 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 41 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 High cost of CRRT to negatively impact market growth
TABLE 42 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 43 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 44 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 45 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 46 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
10.3.1 EUROPEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
TABLE 47 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 49 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 50 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 51 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Largest market for continuous renal replacement therapy in Europe
TABLE 53 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 54 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 55 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 56 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 57 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Rising number of sepsis cases to support market growth
TABLE 58 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 59 UK: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 60 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 61 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 62 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Growing AKI patient population to propel market growth
TABLE 63 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 64 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 65 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 66 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 67 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Government initiatives to promote awareness of renal care to drive market
TABLE 68 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 69 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 70 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 71 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 72 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Favorable reimbursement scenario to favor market growth
TABLE 73 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 74 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 75 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 76 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 77 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 78 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 79 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 80 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 81 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 82 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
FIGURE 36 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT
TABLE 83 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 86 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 87 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 88 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Well-established medical infrastructure to support market growth
TABLE 89 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 90 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 91 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 92 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 93 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Increasing prevalence of ESRD and AKI to boost demand for CRRT
TABLE 94 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 95 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 96 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 97 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 98 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Large patient population to support market growth
TABLE 99 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 100 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 101 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 102 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 103 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 AUSTRALIA
10.4.5.1 Government initiatives to increase adoption of CRRT
TABLE 104 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 105 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 106 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 107 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 108 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.6 SOUTH KOREA
10.4.6.1 Increasing awareness through online education programs and events to aid market growth
TABLE 109 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 110 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 111 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 112 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 113 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.7 REST OF ASIA PACIFIC
TABLE 114 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 115 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 116 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 117 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 118 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 LATIN AMERICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
TABLE 119 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 120 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 121 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 122 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 123 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 124 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.2 BRAZIL
10.5.2.1 Rising incidence of AKI to drive market
TABLE 125 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 126 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 127 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 128 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 129 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.3 MEXICO
10.5.3.1 Large patient population to drive market
TABLE 130 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 131 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 132 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 133 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 134 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.4 REST OF LATIN AMERICA
TABLE 135 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 136 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 138 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 139 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 LACK OF AWARENESS REGARDING CRRT TO RESTRAIN MARKET GROWTH
10.6.2 MIDDLE EAST AND AFRICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
TABLE 140 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 141 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 142 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 143 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
TABLE 144 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
FIGURE 37 GROWTH STRATEGIES ADOPTED BY KEY PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
11.2 REVENUE SHARE ANALYSIS OF MARKET PLAYERS, 2018–2022 (USD MILLION)
FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
FIGURE 39 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
TABLE 145 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DEGREE OF COMPETITION
11.3 COMPANY EVALUATION MATRIX
11.3.1 STARS
11.3.2 EMERGING LEADERS
11.3.3 PERVASIVE PLAYERS
11.3.4 PARTICIPANTS
FIGURE 40 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPANY EVALUATION MATRIX, 2022
11.4 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
11.4.1 PROGRESSIVE COMPANIES
11.4.2 STARTING BLOCKS
11.4.3 RESPONSIVE COMPANIES
11.4.4 DYNAMIC COMPANIES
FIGURE 41 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
11.5 FOOTPRINT ANALYSIS OF PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
TABLE 146 PRODUCT, REGIONAL, AND END-USER FOOTPRINT ANALYSIS OF PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
TABLE 147 PRODUCT FOOTPRINT OF COMPANIES
TABLE 148 END-USER FOOTPRINT OF COMPANIES
TABLE 149 REGIONAL FOOTPRINT OF COMPANIES
11.6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: PRODUCT LAUNCHES AND REGULATORY APPROVALS (JANUARY 2019 TO AUGUST 2023)
TABLE 150 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
11.7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DEALS (JANUARY 2019 TO AUGUST 2023)
TABLE 151 KEY DEALS
11.8 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: OTHER DEVELOPMENTS (JANUARY 2019 TO AUGUST 2023)
TABLE 152 OTHER KEY DEVELOPMENTS
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1 MAJOR PLAYERS
12.1.1 BAXTER INTERNATIONAL, INC.
TABLE 153 BAXTER INTERNATIONAL, INC.: BUSINESS OVERVIEW
FIGURE 42 BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022)
TABLE 154 BAXTER INTERNATIONAL, INC.: PRODUCT OFFERINGS
12.1.2 FRESENIUS MEDICAL CARE AG & CO. KGAA
TABLE 155 FRESENIUS MEDICAL CARE AG & CO. KGAA: BUSINESS OVERVIEW
FIGURE 43 FRESENIUS MEDICAL CARE AG & CO. KGAA: COMPANY SNAPSHOT (2022)
TABLE 156 FRESENIUS MEDICAL CARE AG & CO. KGAA: PRODUCT OFFERINGS
12.1.3 NIKKISO CO., LTD.
TABLE 157 NIKKISO CO., LTD.: BUSINESS OVERVIEW
FIGURE 44 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022)
TABLE 158 NIKKISO CO., LTD.: PRODUCT OFFERINGS
12.1.4 B. BRAUN MELSUNGEN AG
TABLE 159 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
FIGURE 45 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2022)
TABLE 160 B. BRAUN MELSUNGEN AG: PRODUCT OFFERINGS
12.1.5 MEDTRONIC PLC
TABLE 161 MEDTRONIC PLC: BUSINESS OVERVIEW
FIGURE 46 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)
TABLE 162 MEDTRONIC PLC: PRODUCT OFFERINGS
12.1.6 ASAHI KASEI CORPORATION
TABLE 163 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
FIGURE 47 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 164 ASAHI KASEI CORPORATION: PRODUCT OFFERINGS
12.1.7 TORAY MEDICAL CO., LTD.
TABLE 165 TORAY MEDICAL CO., LTD.: BUSINESS OVERVIEW
FIGURE 48 TORAY MEDICAL CO., LTD.: COMPANY SNAPSHOT (2022)
TABLE 166 TORAY MEDICAL CO., LTD.: PRODUCT OFFERINGS
12.1.8 NIPRO CORPORATION
TABLE 167 NIPRO CORPORATION: BUSINESS OVERVIEW
FIGURE 49 NIPRO CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 168 NIPRO CORPORATION: PRODUCT OFFERINGS
12.1.9 INFOMED SA
TABLE 169 INFOMED SA: BUSINESS OVERVIEW
TABLE 170 INFOMED SA: PRODUCT OFFERINGS
12.1.10 MEDICA SPA
TABLE 171 MEDICA SPA: BUSINESS OVERVIEW
TABLE 172 MEDICA SPA: PRODUCT OFFERINGS
12.1.11 MEDITES PHARMA SPOL. S.R.O.
TABLE 173 MEDITES PHARMA SPOL. S.R.O.: BUSINESS OVERVIEW
TABLE 174 MEDITES PHARMA SPOL. S.R.O.: PRODUCT OFFERINGS
12.1.12 MEDICAL COMPONENTS, INC.
TABLE 175 MEDICAL COMPONENTS, INC.: BUSINESS OVERVIEW
TABLE 176 MEDICAL COMPONENTS, INC.: PRODUCT OFFERINGS
12.1.13 SWS HEMODIALYSIS CARE CO., LTD.
TABLE 177 SWS HEMODIALYSIS CARE CO., LTD.: BUSINESS OVERVIEW
TABLE 178 SWS HEMODIALYSIS CARE CO., LTD.: PRODUCT OFFERINGS
12.1.14 NINGBO TIANYI MEDICAL DEVICES CO., LTD.
TABLE 179 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: BUSINESS OVERVIEW
TABLE 180 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: PRODUCT OFFERINGS
12.1.15 ANJUE MEDICAL EQUIPMENT CO., LTD.
TABLE 181 ANJUE MEDICAL EQUIPMENT CO., LTD.: BUSINESS OVERVIEW
TABLE 182 ANJUE MEDICAL EQUIPMENT CO., LTD.: PRODUCT OFFERINGS
12.1.16 KIMAL
TABLE 183 KIMAL: BUSINESS OVERVIEW
TABLE 184 KIMAL.: PRODUCT OFFERINGS
12.1.17 JIANGXI SANXIN MEDTEC CO., LTD.
TABLE 185 JIANGXI SANXIAN MEDTECH CO., LTD.: BUSINESS OVERVIEW
TABLE 186 JIANGXI SANXIAN MEDTECH CO., LTD.: PRODUCT OFFERINGS
12.2 OTHER PLAYERS
12.2.1 ALLMED MEDICAL PRODUCTS CO., LTD.
12.2.2 DIALCO MEDICAL INC.
12.2.3 BROWNDOVE HEALTHCARE PVT. LTD.
12.2.4 STERIS PLC
12.2.5 KURARAY MEDICAL PLC
12.2.6 LIVANOVA PLC
12.2.7 DIAVERUM DEUTSCHLAND GMBH
12.2.8 SEMBCORP INDUSTRIES
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
